Edap Tms (NASDAQ:EDAP - Get Free Report) was upgraded by investment analysts at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Thursday.
Separately, HC Wainwright raised their target price on shares of Edap Tms from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Monday, April 1st.
Get Our Latest Stock Analysis on EDAP
Edap Tms Price Performance
EDAP traded down $0.43 during midday trading on Thursday, hitting $7.84. The company had a trading volume of 34,840 shares, compared to its average volume of 40,423. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.30 and a current ratio of 2.84. The company has a market capitalization of $289.37 million, a PE ratio of -12.44 and a beta of 0.74. Edap Tms has a twelve month low of $3.60 and a twelve month high of $12.23. The firm's 50-day simple moving average is $7.01 and its 200-day simple moving average is $6.24.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of EDAP. Rock Springs Capital Management LP boosted its stake in Edap Tms by 14.6% during the 3rd quarter. Rock Springs Capital Management LP now owns 1,360,000 shares of the medical equipment provider's stock worth $9,547,000 after acquiring an additional 173,700 shares during the last quarter. Milestone Investment Advisors LLC bought a new position in Edap Tms during the 3rd quarter worth approximately $39,000. Summit Trail Advisors LLC bought a new position in Edap Tms during the 3rd quarter worth approximately $77,000. Royal Bank of Canada boosted its stake in Edap Tms by 22.5% during the 2nd quarter. Royal Bank of Canada now owns 18,375 shares of the medical equipment provider's stock worth $169,000 after acquiring an additional 3,375 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in Edap Tms by 113.9% during the 2nd quarter. BlackRock Inc. now owns 28,936 shares of the medical equipment provider's stock worth $267,000 after acquiring an additional 15,409 shares during the last quarter. Institutional investors own 62.74% of the company's stock.
About Edap Tms
(
Get Free Report)
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST).
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Edap Tms, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edap Tms wasn't on the list.
While Edap Tms currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
